AstraZeneca's long-term GLP-1 play is weight management, not obesity, CEO says
A day after AstraZeneca inked a new $185 million licensing deal to reenter the GLP-1 frenzy, CEO Pascal Soriot says the future marketplace will center less on treating obesity and more on sustained weight management. “One of the key pieces for us is to have an agent that will target those people…
#astrazeneca #glp1 #pascalsoriot #elililly #novonordisk #bmi #aradhanasarin #lilly